Cargando…

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

Detalles Bibliográficos
Autores principales:	Banna, G L, Aversa, S M L, Crivellari, G, Ghiotto, C, Chiarion-Sileni, V, Monfardini, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361276/ https://www.ncbi.nlm.nih.gov/pubmed/16641905 http://dx.doi.org/10.1038/sj.bjc.6603114

Ejemplares similares

Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update
por: Erotocritou, P., et al.
Publicado: (2006)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation
por: Toh, H C, et al.
Publicado: (2011)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation
por: Imamura, Masahiro, et al.
Publicado: (2009)

Allogeneic bone marrow transplantation can suppress established and otherwise chronic collagen-induced arthritis after a nonmyeloablative conditioning regimen employing anti-CD40 ligand monoclonal antibody
por: Flierman, R, et al.
Publicado: (2004)

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
por: Kanda, Junya, et al.
Publicado: (2011)

Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning
por: De Bock, Muriel, et al.
Publicado: (2013)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin
por: Veltri, Lauren, et al.
Publicado: (2013)

Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation
por: Kim, Nayoun, et al.
Publicado: (2015)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning
por: Schwaiger, Elisabeth, et al.
Publicado: (2012)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Extension of Maximal Lifespan and High Bone Marrow Chimerism After Nonmyeloablative Syngeneic Transplantation of Bone Marrow From Young to Old Mice
por: Kovina, Marina V., et al.
Publicado: (2019)

A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma
por: Yu, K., et al.
Publicado: (2018)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Autologous nonmyeloablative hematopoietic stem cell transplantion in newly diagnosed childhood type 1 diabetes mellitus: the first year report
por: Luo, Feihong, et al.
Publicado: (2013)

Small molecules and targeted therapies in distant metastatic disease
por: Hersey, P., et al.
Publicado: (2009)

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy
por: Penaforte-Saboia, Jaquellyne G., et al.
Publicado: (2017)

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
por: Liu, Wei-Hsin, et al.
Publicado: (2015)

Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia
por: Chen, Rong-Long, et al.
Publicado: (2022)

Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation
por: Nayak, Deepak Kumar, et al.
Publicado: (2016)

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
por: Morin-Zorman, Sarah, et al.
Publicado: (2016)

Small Split Doses of CD34(+) Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy
por: Yankelevich, Maxim, et al.
Publicado: (2017)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
por: Valpione, Sara, et al.
Publicado: (2015)

Adjuvant! Online or comprehensive geriatric assessment for women over 70 years with primary breast cancer?
por: Monfardini, S, et al.
Publicado: (2012)

The safety and effectiveness of genetically corrected iPSCs derived from β-thalassaemia patients in nonmyeloablative β-thalassaemic mice
por: Xian, Yexing, et al.
Publicado: (2020)

Antibody based conditioning for allogeneic hematopoietic stem cell transplantation
por: Saha, Asim, et al.
Publicado: (2022)

Administration of Hydrogen-Rich Saline in Mice with Allogeneic Hematopoietic Stem-Cell Transplantation
por: Yuan, Lijuan, et al.
Publicado: (2015)

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
por: Cecchini, Michael, et al.
Publicado: (2015)

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer
por: Karadurmus, Nuri, et al.
Publicado: (2018)

Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation
por: de Jong, G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6qvuvg3ninjlfs71muq66r72dr